Undisclosed anti-Trop2 ProTriTAC / Merck (MSD) - LARVOL DELTA

TROP2 ProTriTAC™, a protease-activated T cell engager prodrug targeting TROP2 for the treatment of solid tumors (AACR 2023) - "Toxicokinetics, gross pathology, histopathology, and cytokine data will be presented. The preclinical activity in rodent tumor models, coupled to its tolerability in cynomolgus monkeys, support the development of anti-Trop2 ProTriTAC as a therapeutic in a broad range of Trop2-expressing solid tumors."

Bladder Cancer • Genito-urinary Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Urothelial Cancer • TACSTD2 • TROP2

Harpoon Therapeutics Presents Data for New ProTriTAC Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023 (GlobeNewswire) - "Harpoon Therapeutics...presented preclinical data on two new development candidates from the proprietary ProTriTAC™ platform in TROP2- and ITGB6-expressing solid tumors in poster presentations at the American Association for Cancer Research (AACR) Annual Meeting....In rodent established tumor models, TROP2 ProTriTAC had highly potent anti-tumor activity in vivo with complete tumor eradication at doses as low as 30 µg/kg. In cynomolgus monkeys, TROP2 ProTriTAC showed favorable pharmacokinetics and was well-tolerated up to 180 µg/kg, whereas 540 µg/kg triggered on-target toxicity with mixed cell infiltrates in organs where normal tissue expression of TROP2 is expected."

Preclinical • Oncology • Solid Tumor

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) - "AACR 2023 – Five Preclinical Posters to be Presented: HPN217: Preclinical abstract to be presented at AACR on April 18, 2023. HPN328: Two preclinical abstracts to be presented at AACR on April 18, 2023. ProTriTAC: Two preclinical abstracts to be presented at AACR on April 17, 2023."

Preclinical • Hematological Malignancies • Oncology • Solid Tumor